(Bloomberg) — Royal Philips NV said it will set aside a provision of €575 million ($630 million) in the US to compensate patients’ economic loss as part of a costly recall of millions of medical devices to treat sleep apnea.
The funds add to provisions the Dutch medical-equipment maker has been making after initiating its first recall of potentially faulty sleep apnea products in June 2021.
Philips has set aside almost €1 billion for the recall of around 5.5 million devices globally, of which more than half are in the U. S.
The company also reported first-quarter adjusted earnings before interest, taxes and amortization came of €359 million. That beat the average estimate of €212 million in a Bloomberg survey of analysts.
Philips has warned it might need to increase provisions as user lawsuits progress.
Customers have alleged that inhaling the foam after it disintegrates poses a cancer risk. In addition to economic compensation for clients, Philips also faces medical monitoring class action and personal injury claims in the US.
More stories like this are available on bloomberg.com
©2023 Bloomberg L. P.
